BNP Paribas Financial Markets Buys 34,450 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

BNP Paribas Financial Markets boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 122.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,631 shares of the biopharmaceutical company's stock after purchasing an additional 34,450 shares during the period. BNP Paribas Financial Markets owned about 0.09% of Celldex Therapeutics worth $1,583,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Ameriprise Financial Inc. purchased a new stake in Celldex Therapeutics in the 4th quarter valued at approximately $251,000. Algert Global LLC raised its stake in Celldex Therapeutics by 89.8% during the fourth quarter. Algert Global LLC now owns 104,337 shares of the biopharmaceutical company's stock worth $2,637,000 after acquiring an additional 49,354 shares during the period. Novo Holdings A S increased its holdings in shares of Celldex Therapeutics by 3.8% in the 4th quarter. Novo Holdings A S now owns 1,000,000 shares of the biopharmaceutical company's stock worth $25,270,000 after acquiring an additional 36,337 shares during the period. Northern Trust Corp boosted its holdings in shares of Celldex Therapeutics by 6.2% in the fourth quarter. Northern Trust Corp now owns 597,605 shares of the biopharmaceutical company's stock valued at $15,101,000 after acquiring an additional 34,885 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in Celldex Therapeutics during the fourth quarter valued at about $822,000.

Celldex Therapeutics Trading Down 0.7%

Shares of CLDX stock traded down $0.15 during trading on Friday, reaching $20.22. 173,688 shares of the company's stock traded hands, compared to its average volume of 892,807. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $47.00. The company has a market capitalization of $1.34 billion, a P/E ratio of -7.87 and a beta of 1.39. The firm's 50-day moving average is $18.90 and its 200 day moving average is $22.45.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLDX has been the subject of several recent analyst reports. The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Morgan Stanley cut their target price on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. UBS Group dropped their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.